Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.37 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28242379 | 0.81 | LMNA (0.43) | HPGDTSHRMAPK1HSD17B10LMNA | |
| SCHEMBL476633 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1 | |
| SCHEMBL10889456 | 0.79 | HPGD (0.42) | HPGDTSHRMAPK1HSD17B10LMNA | |
| SCHEMBL10889468 | 0.79 | HPGD (0.42) | HPGDTSHRMAPK1HSD17B10LMNA | |
| SCHEMBL4893011 | 0.76 | LMNA (0.46) | HPGDTSHRLMNAALDH1A1HTT | |
| SCHEMBL14931402 | 0.73 | GABRA1 (0.45) | HPGDTSHRMAPK1HSD17B10LMNA | |
| SCHEMBL14931403 | 0.73 | GABRA1 (0.45) | HPGDTSHRMAPK1HSD17B10LMNA | |
| SCHEMBL4909050 | 0.71 | GABRA1 (0.46) | HPGDTSHRHSD17B10LMNAALDH1A1 | |
| SCHEMBL7789589 | 0.71 | — | — | |
| SCHEMBL6779682 | 0.71 | FGF23 (0.57) | HPGDTSHRMAPK1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501859-B1 | 17a-FLUOROALKYL-11BETA-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS | SCHERING AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-6825182-B2 | FOR POSTMENOPAUSAL SUBSTITUTION THERAPY OF GYNECOLOGICAL DISEASES, SUCH AS HYSTEROMYOMAS OR DYSMENORRHOIC SYMPTOMS | SCHERING AG (DE) | 2004-11-30 | — | — | US | claimed |
| US-20040092492-A1 | 17alpha-fluoroalkyl-11beta-benzaldoxime steroids, process for their production, pharmaceutical preparations that contain these steroids as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2004-05-13 | — | — | US | claimed |
| US-6825182-B2 | FOR POSTMENOPAUSAL SUBSTITUTION THERAPY OF GYNECOLOGICAL DISEASES, SUCH AS HYSTEROMYOMAS OR DYSMENORRHOIC SYMPTOMS | SCHERING AG (DE) | 2004-11-30 | — | — | US | disclosed |
| US-6825182-B2 | FOR POSTMENOPAUSAL SUBSTITUTION THERAPY OF GYNECOLOGICAL DISEASES, SUCH AS HYSTEROMYOMAS OR DYSMENORRHOIC SYMPTOMS | SCHERING AG (DE) | 2004-11-30 | — | — | US | disclosed |
| US-20040092492-A1 | 17alpha-fluoroalkyl-11beta-benzaldoxime steroids, process for their production, pharmaceutical preparations that contain these steroids as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20040092492-A1 | 17alpha-fluoroalkyl-11beta-benzaldoxime steroids, process for their production, pharmaceutical preparations that contain these steroids as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092492-A1 | 17alpha-fluoroalkyl-11beta-benzaldoxime steroids, process for their production, pharmaceutical preparations that contain these steroids as well as their use for the production of pharmaceutical agents | CBR1, CYP4B1, CYP21A2 | HPGD 636/4885TSHR 266/4885MAPK1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.